The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

Phase 2

Completed

• Conditions: Varicella
• Interventions: Biological: NBP608; Biological: Varivax

• Registration Number: NCT03114982
• Lead Sponsor: SK Chemicals Co., Ltd.

Brief Summary

This study evaluates the immunogenicity and safety of three different potencies of NBP608 and Varivax which are indicated for active immunization for the prevention of varicella. Total of 152 subjects (38 subjects per each treatment arm) of 12 months to 12 years of age are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Detailed Description

This is a multi-center, randomized, double blinded, active controlled, parallel-group study to evaluate the immunogenicity and safety of three different potencies of NBP608(low, middle, high potency) and Varivax which are indicated for active immunization for the prevention of varicella. Total of 152 subjects (38 subjects per each treatment arm) of 12 months to 12 years of age are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned in 1:1:1:1 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata.

Total of four visits are scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks after vaccination at Visit 1 and Visit 3 respectively. Safety is monitored 1 week, 6 weeks and 26 weeks after vaccination through Visit 2\*, Visit 3 and Visit 4\* (\*telephone contact)

Study Timeline

• Study Start: 2016-05
• Primary Completion: 2016-07
• Study Completion: 2016-11
• Status Verified: 2017-04
• Study First Submitted: 2017-04-11
• Study First Submitted QC: 2017-04-11
• Last Update Submitted: 2017-04-11
• Study First Posted: 2017-04-14
• Last Update Posted: 2017-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

• Healthy children aged between 12 months and 12 years old who are available for the follow-up during the study period
• After menarche females who are confirmed to be negative in a pregnancy test on the day of vaccination and agree to practice birth control for 3 months after the vaccination

Exclusion Criteria

• Those with hypersensitivity to any component of the IPs(Investigational Products), such as gelatin or neomycin
• Those who have received a varicella vaccine previously
• Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome
• Those with congenital or acquired immunodeficiency
• Those with active untreated tuberculosis
• Those who have received or are expected to receive salicylates from 14 days prior to IP(Investigational Product) vaccination to Visit 3
• Those who have received or are expected to receive other vaccines from 1 month prior to IP(Investigational Product) to Visit 3
• Those who have received or are expected to receive other IPs(Investigational Products) in another clinical study from 1 month prior to IP(Investigational Product) vaccination to Visit 3

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Middle potency of NBP608	NBP608	Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
Varivax	Varivax	Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
Low potency of NBP608	NBP608	Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
High potency of NBP608	NBP608	Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh

Primary Outcome Measures

Name	Time	Method
Seroconversion rate measured by FAMA(Fluorescent Antibody to Membrane Antigen) assay	6 weeks after IP(Investigational Product) vaccination	\*FAMA(Fluorescent Antibody to Membrane Antigen) Seroconversion Rate: the rate of subjects who are converted from seronegative with FAMA(Fluorescent Antibody to Membrane Antigen) VZV(Varicella Zoster Virus) antibody titer \< 1:4 before IP(Investigational Product) vaccination to seropositive with FAMA(Fluorescent Antibody to Membrane Antigen) VZV(Varicella Zoster Virus) antibody titer ≥ 1:4 at 6 weeks post-vaccination

Secondary Outcome Measures

Name	Time	Method
VZV (Varicella Zoster Virus) antibody GMT (Geometric Mean Titer) measured by FAMA(Fluorescent Antibody to Membrane Antigen) assay	6 weeks after IP(Investigational Product) vaccination
VZV (Varicella Zoster Virus) antibody GMT (Geometric Mean Titer) measured by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay)	6 weeks after IP(Investigational Product) vaccination
Seroconversion rate measured by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay)	6 weeks after IP(Investigational Product) vaccination	\*gpELISA Seroconversion Rate : the rate of subjects who are converted from seronegative with \< 50mIU/mL before IP vaccination to seropositive with ≥ 50mIU/mL at 6 weeks post-vaccination

Trial Locations

Locations (1)

Research Insitute for Torpical Medicine; 🇵🇭 Muntinlupa City, Metro Manila, Philippines